ArticleBrain and behavior2025
Quantitative Electroencephalographic Biomarkers for Repetitive Transcranial Magnetic Stimulation Treatment Response Prediction in Mild Cognitive Impairment: A Pilot Study Protocol for Multi-Center, Assessor-Blinded, Open-Label Clinical Trial.
Article in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Quantitative electroencephalography as a next-generation tool in neurodiagnostics: significance, clinical applications, and practical interpretative frameworks.Frontiers in neuroscience · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
rationaleOver 55 million people worldwide suffer from dementia, with 10 million new cases diagnosed annually. Due to the limited efficacy of drug therapies, alternative approaches like repetitive transcranial magnetic stimulation (rTMS) have gained popularity as a non-invasive, safe method leveraging neural plasticity and brain connectivity. However, its high cost and time commitment highlight the need for biomarkers to predict treatment response.
aimsThis pilot study aims to identify a quantitative electroencephalography (QEEG) biomarker to predict which mild cognitive impairment patients will respond to rTMS. By targeting responders early, clinicians can make rTMS more cost-effective and time-efficient, reducing wasted treatment on non-responders.
designThis multi-center, assessor-blinded clinical trial will examine QEEG biomarkers as predictors of rTMS treatment responsiveness in 25 patients with mild cognitive impairment (MCI). Adults aged 60 years or older will undergo cognitive assessments using the Montreal Cognitive Assessment (MoCA) or mini-mental state examination (MMSE) and have an electroencephalography (EEG) recording. Participants will complete 10 rTMS sessions targeting the left DLPFC over 2 weeks, with 2000 pulses per session at 20 Hz. Cognitive tests will be repeated post-treatment, and participants will be classified as responders or non-responders based on cognitive changes, then baseline QEEG parameters will be compared between the two groups. The primary endpoint is the proportion of responders at ten sessions after rTMS (score post-intervention > score pre-intervention = responder, according to the minimal clinically important difference (MCID) threshold (i.e., an increase of at least 3 points or 10% on the MMSE, or an increase of at least 1 point on the MoCA); score post-intervention ≤ score pre-intervention = non-responder). The secondary endpoints are the differences in baseline QEEG features between responders and non-responders. OUTCOME: By identifying responders prior to treatment, we can optimize resource allocation, minimize the time and cost associated with ineffective treatments, and ultimately improve the quality of care for individuals with MCI.
trial registrationIRCT registration number: IRCT20240218061042N1 (version updated September 7, 2024).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.